Raman spectroscopy aided evaluation of basal cell carcinoma diagnosis: A case report.

Photodiagnosis Photodyn TherAug 7, 2026 (epub)
Case ReportDermatology

Minfeng Wu, Shiyi Yang, Zhe Zheng et al.

✦ AI-curated · Sources linked

Case in brief

A 93-year-old patient presented with a suspicious scalp lesion. Initial clinical evaluations indicated a malignant lesion, but the specific type remained undetermined. In vivo Raman spectroscopy revealed spectral similarities to previous basal cell carcinoma (BCC) cases, aiding in differentiation from actinic keratosis. Despite an initial benign histopathological assessment, expert review and immunohistochemistry confirmed BCC, supporting the Raman findings.

Diagnostic / clinical pearl

Raman spectroscopy can provide valuable adjunctive information in diagnosing basal cell carcinoma, particularly in cases where conventional methods yield inconclusive results.

Why it matters

This case highlights the potential of non-invasive techniques like Raman spectroscopy to enhance diagnostic accuracy for challenging skin lesions, potentially reducing reliance on invasive biopsies.

Source

PubMed · PMID 42567338

Published in Photodiagnosis Photodyn Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Dermatology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.